A Three-Part Study Evaluating the Pharmacokinetics of Intravenous (IV) Danoprevir (DNV)/Oral Low-Dose Ritonavir (RTV), the Absolute Bioavailability of DNV With and Without Oral Low-Dose RTV, and the Effect of Oral Cyclosporine on IV DNV/Oral Low-Dose RTV in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Danoprevir (Primary) ; Danoprevir (Primary) ; Ciclosporin; Ritonavir
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 25 Feb 2013 Actual end date (Jan 2013) added as reported by ClinicalTrials.gov.
- 03 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.